Nuovi laboratori Controllo Qualit e Ricerca & Sviluppo
Posa della prima pietra
26 febbraio 2015
Bogdan Oghina
Enrico Cozzi
Carlos Villalobos
Antonella Martignoni
Vera Terragni
Lorena Muggetti
Claudio Zaninetti
Managing Director, Injectables
Major of Nerviano
VP, Injectables and Biologics
Executive Director, Quality Injectables/Biosimilars
Quality Operations Director
Research & Development Director
Engineering, Maintenance & Utilities Director
I relatori
Actavis
Actavis (NYSE:ACT) markets a broad portfolio of branded and generic pharmaceuticals and
develops innovative medicines for patients suffering from diseases principally in the Central Nervous
System, Gastroenterology, Womens Health, Urology, Cardiovascular, Respiratory and Anti-infective
therapeutic categories.
The Company is an industry leader in R&D, with one of the broadest brand development pipelines in
the pharmaceutical industry, and a leader in the submission of generic product applications. Actavis
has commercial operations in 60+ countries and operates 30+ manufacturing and distribution
facilities around the world.
3
Actavis by the Numbers
Commercial Operations in 60+ Countries
Markets/Distributes
nearly 1,000 products
30+ manufacturing facilities
20+ R&D centers
~44+ billion unit capacity
25+ specialty brand products
in near or mid-term stage of
development
Our business
Evolution of Actavis 1984 - Today
1984
Expanding Global Generics
2006 - 2012
Emerging Brand and
Specialty Global
Company
2013 - 2014
November 17, 2014
6
Announced November 17, 2014
An Exceptional Transaction Announced November 17, 2014
Creates a New Top 10 Global Growth Pharmaceutical
Company
- $23B of pro forma revenue in 2015
$66B cash and stock deal at $219 per share
Approved by both Boards; strongly supported by both
management teams
- Subject to shareholder approval of both companies; customary
regulatory approvals
- Anticipate the transaction to close in the second quarter of 2015
Industry-leading combined management team led by Brent
Saunders, CEO and President and Paul Bisaro, Executive
Chairman
8
The Most Dynamic Company in Growth Pharma An Exceptional Company by the Numbers
Double-
Digit %
Accretion
10+%
Revenue
Growth
Target
>30,000 Employees
$8B Free Cash
Flow in 2016
~$23B Global
Revenue
~$1.7B R&D Spend
~$147B Enterprise
Value
2017
Aspiration
$25 EPS
9
Creating the Most Dynamic Company in
Growth Pharma
10
$15 Billion Global Brand Portfolio 6 Blockbuster Franchises & Strong Anti-Infectives/Established Brands Franchises
Acta
vis
A
llerg
an
Womens Health
& Urology Ophthalmology CNS
Cardiovascular &
Respiratory
GI &
Cystic Fibrosis
Dermatology &
Aesthetics
~$3 Billion+ ~$3 Billion+ ~$3 Billion+ $1 Billion+ $1 Billion+ $1 Billion+
Anti-infectives &
Est. Brands
http://www.google.com/url?url=http://www.frx.com/Products&rct=j&frm=1&q=&esrc=s&sa=U&ei=awJbVKLQM4iVyQTskYLYDA&ved=0CBgQ9QEwAQ&usg=AFQjCNGbappa2IUvamsCDaV-Qsi42WeV0whttp://www.google.com/url?url=http://www.practiceofmadness.com/2013/11/medical-advertising-images/&rct=j&frm=1&q=&esrc=s&sa=U&ei=xgNbVOijMderyAST_IK4CQ&ved=0CBYQ9QEwAA&usg=AFQjCNH9im1Bjg148vYxO_O7_toMpul1Awhttp://www.google.com/url?url=http://medcitynews.com/2009/10/schering-plough-launches-schizophrenia-bi-polar-disorder-drug-after-buying-maker/saphris-logo/&rct=j&frm=1&q=&esrc=s&sa=U&ei=S_ZgVOzqLoi5yQTehoGwCg&ved=0CBYQ9QEwAA&usg=AFQjCNGjGX--prdebKOrX7ztB_9-DHTTqwhttp://www.google.com/url?url=http://www.frx.com/Products&rct=j&frm=1&q=&esrc=s&sa=U&ei=OgNbVOTzKpS0yATr9oLQDQ&ved=0CBoQ9QEwAg&usg=AFQjCNG5uN2Fw1rzkQqY3a_1_MCnrht7Gwhttp://www.google.com/url?url=http://www.tudorzahcp.com/&rct=j&frm=1&q=&esrc=s&sa=U&ei=ufdgVIfoGZOVyATd34D4DA&ved=0CBYQ9QEwAA&usg=AFQjCNHSgwjCHlXnpstCYLiGmtmkmsj2PQhttp://www.google.com/url?url=http://www.daliresp.com/&rct=j&frm=1&q=&esrc=s&sa=U&ei=1_dgVN_wIcueyAS-voKABw&ved=0CBgQ9QEwAA&usg=AFQjCNH69-cEr0ZPJLLIJDUi8x5dOtdrhQhttp://www.google.com/url?url=http://thuocthang.vn/tin-tuc/thong-tin-duoc/linzess-thuoc-moi-dieu-tri-hoi-chung-ruot-kich-thich-va-tao-bon/269.aspx&rct=j&frm=1&q=&esrc=s&sa=U&ei=DgNbVMelOZKjyAShk4LgDg&ved=0CBoQ9QEwAg&usg=AFQjCNEIod1CmfmJRTNt4SVOBlBtAqbEWAhttps://www.google.com/url?url=https://www.zenpep.com/&rct=j&frm=1&q=&esrc=s&sa=U&ei=9flgVJOrE8GjyATgvoHADg&ved=0CBYQ9QEwAA&usg=AFQjCNFht523454lGbGePCv_wFHg646UlAhttps://www.google.com/url?url=https://coupondoc.com/coupons/127-lumigan&rct=j&frm=1&q=&esrc=s&sa=U&ei=Icm0U5GTIdSmyATd74HoDA&ved=0CBoQ9QEwAg&usg=AFQjCNFm-_VFBGYIP--ZMhODcTDYxvBSSw
Unparalleled Commercial Reach
Presence in 100 Countries
with Greater Market and
Product Reach A leader in growing
markets including Europe,
Southeast Asia, China, India
and Latin America
World-class commercial sales and marketing organization
competing across multiple market segments Brands, generics, branded-generics, OTC
12
BOTOX CFL Asia
BOTOX Forehead Lines
BOTOX Spasticity Adult LL, Adult UL, Ped LL,
Ped UL
RESTASIS EU
Bimatoprost SR
DARPin AMD
SEMPRANA Headache
LATISSE Brow
Oxymetazoline Rosacea
ACZONE X
SER-120
OZURDEX RVO China
LASTACAFT Japan
Bystolic + valsartan
Namenda + donepezil
Levonorgestrel-releasing intrauterine system
(LNG20)
CAZ-AVI
Viibryd Low- Dose
Eluxadoline
Cariprazine
Esmya
Sarecylcline
Industry-leading Generics Pipeline
60+ First to Files, 228 pending ANDAs
1,200+ Pending MAAs Internationally
Actavis Brands Allergan
~$1.7 Billion Commitment to R&D
Strong Late Stage Pipeline
Actavis Generics
Committed to ~$1.7 Billion Combined R&D Investment
Industry-leading Global Supply Chain
Actavis Injectable Business
Global Injectables Business is Supplied
from two European Facilities
Bucharest (Sindan), Romania:
Role
The origin of the Actavis oncology
business
Small, flexible, niche
Production capabilities:
Cytotoxic freeze-dried and solution
products in vials; SOD (tablets and
capsules)
Annual production volume: ~3M vials & 30M
tab/cps
Approximately 250 employees
Nerviano, Italy:
Role
Delivering scale and capacity
Long history of global supply (formerly a
Pfizer facility)
Production Capabilities:
Containment, Cytotoxic and non-
Cytotoxic freeze-dried and Solution
products in Vials, Amps and Pre-Filled
Syringes
Annual production volume: >25-35 million
vials depending on product mix
Approximately about 450 employees
Diversifying US Generic Portfolio into Alternate Dosage Forms
Other
Hormones
Buccal Transdermal
Oral Liquid
Ophthalmic & Optic
Injectable
Topical
MR Oral Solid
IR Oral Solid
Inhalation
In Market Filed at FDA
In Development
Chart: % of development projects based on # of products in each dosage form
18
Firm believe in excellence and commitment to quality
Increased R&D capabilities
Vital to be competitive in price and supply of our medicines
Engagement and cooperation with our employees, unions, suppliers and
business partners
Video
19
Why invest in Italy, when our competitors invest elsewhere?
20
Actavis Nerviano
21
Actavis Italy SpA
Via L. Pasteur, 10 20014 Nerviano (MI) - Italy
About Nerviano
Nerviano La storia
1969: Farmitalia costruisce lo stabilimento di Nerviano, dedicato alluso veterinario
1975: Farmitalia trasferisce la produzione delle antracicline
1980: Farmitalia acquisisce Carlo Erba e forma Farmitalia Carlo Erba (FICE)
1982: FICE sposta la produzione di tutti gli iniettabili e di tutte le attivit R&D a Nerviano
1994: Kabi Pharmacia acquisisce FICE e forma Pharmacia
1996: Pharmacia si fonde con Upjohn e nasce Pharmacia & Upjohn
2000: Pharmacia & Upjohn si fonde con Monsanto e nasce Pharmacia
2003: Pfizer acquisisce Pharmacia. Pfizer Italy acquisisce Nerviano
2004: Pfizer Italia vende il Centro Ricerche a NMS
2008: Actavis acquisis
